Herpes Zoster em Pacientes com Artrite Inflamatória ou Colite Ulcerativa Tratados com Tofacitinib, Baricitinib ou Upadacitinib: uma revisão sistemática de estudos clínicos e do mundo real
Overall, this evidence supports that HZ-risk is a “class” effect of JAKi, observing a higher risk compared to other non-biologic/biologic drugs . This study aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with TOFA, BARI or UPA.
Overall, this evidence supports that HZ-risk is a “class” effect of JAKi, observing a higher risk compared to other non-biologic/biologic drugs . This study aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with TOFA, BARI or UPA.